Values First Advisors, Inc. Immunovant, Inc. Transaction History

Values First Advisors, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$15.27 - $19.72 $74,578 - $96,312	-4,884 Reduced 41.23%	6,962 $107,000
Q4 2022 Jan 20, 2023	SELL	$6.59 - $17.75 $75,119 - $202,332	-11,399 Reduced 49.04%	11,846 $0
Q3 2022 Dec 02, 2022	BUY	$3.93 - $6.37 $2,998 - $4,860	763 Added 3.39%	23,245 $130,000
Q2 2022 Jul 20, 2022	BUY	$3.38 - $5.65 $30,463 - $50,923	9,013 Added 66.92%	22,482 $88,000
Q1 2022 May 03, 2022	BUY	$5.06 - $8.77 $13,105 - $22,714	2,590 Added 23.81%	13,469 $74,000
Q4 2021 Mar 10, 2022	BUY	$7.33 - $9.32 $79,743 - $101,392	10,879 New	10,879 $93,000
Q3 2021 Nov 15, 2022	SELL	$7.01 - $11.37 $78,252 - $126,923	-11,163 Reduced 49.65%	11,319 $98,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Values First Advisors, Inc. with notifications on news.